Hyloris Developments SA
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Tranexamic Acid Oral Solution (US 11,666,532) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 1 fee due Oct 16, 2027The maintenance fee for Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor (US 11,957,648) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,923,447 | Parenteral solutions containing metolazone In force · From the USPTO record | In force | From the USPTO record | |
| US 9,427,398 | Parenteral solutions containing metolazone In force · From the USPTO record | In force | From the USPTO record | |
| US 11,389,451 | Metolazone Emulsion Formulation In force · High confidence | In force | High confidence | |
| US 12,121,520 | Metolazone emulsion formulation In force · From the USPTO record | In force | From the USPTO record | |
| US 11,666,532 | Tranexamic Acid Oral Solution In force · High confidence | In force | High confidence | |
| US 11,413,241 | METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF In force · High confidence | In force | High confidence | |
| US 11,364,213 | Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor In force · High confidence | In force | High confidence | |
| US 11,957,648 | Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor In force · High confidence | In force | High confidence | |
| US 12,343,320 | Intraveneous dofetilide to reduce the risk of developing AF/AFL post coronary bypass surgery In force · From the USPTO record | In force | From the USPTO record | |
| US 12,521,357 | Intravenous Dofetilide to Convert Atrial Fibrillation/Flutter In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 3 abandoned · 2 no status recorded
Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/278,179 | Jul 23, 2025 | No status recorded | |
| 19/276,294 | Use of Vitamin E TPGS as a Taste Masking Agent for Bitter Drugs | Jul 22, 2025 | Abandoned |
| 18/775,374 | Lyophilized Metolazone Formulation for Parenteral Administration | Jul 17, 2024 | Pending |
| 18/610,343 | Method of Initiating or Escalating Dofetilide Dose and Formulations Therefor | Mar 20, 2024 | Pending |
| 18/328,975 | Tranexamic Acid Oral Solution | Jun 5, 2023 | Abandoned |
| 18/855,499 | Aqueous Ticagrelor Solutions, Method of Manufacturing and Uses | May 16, 2023 | Pending |
| 18/175,971 | Intraveneous Dofetilide to Terminate Arrhythmic Storm Following Implantation of a Cardiac Defibrilator | Feb 28, 2023 | Abandoned |
| 16/243,252 | Jan 9, 2019 | No status recorded |